



Impact Analysis Statement

A Summary Impact Analysis Statement (IAS) must be completed for all regulatory proposals.

Summary IAS

Details

Lead department	Queensland Health
Name of the proposal	<i>Medicines and Poisons (Medicines) Amendment Regulation (No. 4) 2023</i>
Submission type (Summary IAS / Consultation IAS / Decision IAS)	Summary IAS
Title of related legislative or regulatory instrument	<i>Medicines and Poisons (Medicines) Regulation 2021</i>
Date	2 November 2023

For proposals noted in table below

Complete and delete rows where applicable. No further analysis is required.

Proposal type	Details
Regulatory proposals where no RIA is required	<p>The <i>Medicines and Poisons (Medicines) Amendment Regulation (No. 4) 2023</i> (Amendment Regulation) will amend the Medicines Regulation to facilitate implementation of the Queensland Community Pharmacy Scope of Practice Pilot (Pharmacy Pilot).</p> <p>The amendments to the Medicines Regulation will reference a new Pharmacy Pilot Extended Practice Authority and enable pharmacists participating in the Pharmacy Pilot to undertake the following dealings with a Schedule 4 (S4) medicine, other than a restricted medicine or diversion-risk medicine:</p> <ul style="list-style-type: none"> • prescribe for the management of specified acute common conditions, as part of a health and wellbeing service or a chronic disease management program; • sell, other than on prescription, to enable continued dispensing; • amend a prescription without the agreement of the prescriber who made the prescription, to enable therapeutic adaptation and therapeutic substitution; and • dispense for the purposes of therapeutic adaptation and substitution. <p>The new Pharmacy Pilot Extended Practice Authority will:</p> <ul style="list-style-type: none"> • state the restrictions and conditions under which medicines may be prescribed including the requirement that a pharmacist may prescribe a medicine for the management of: <ul style="list-style-type: none"> ○ a specified acute common condition or as part of a health and wellbeing service in line with the relevant Pharmacy Pilot clinical practice guideline; and ○ a condition included within a Pharmacy Pilot clinical protocol for cardiovascular disease risk reduction, improved asthma and



	<p>exercise-induced bronchoconstriction symptom control and chronic obstructive pulmonary disease (COPD) monitoring in line with the relevant clinical protocol; and</p> <ul style="list-style-type: none"> state the restrictions and conditions under which participating pharmacists may conduct medication management activities including therapeutic adaptation, therapeutic substitution and continued dispensing. <p>The Amendment Regulation also amends the Medicines Regulation to:</p> <ul style="list-style-type: none"> clarify that enrolled nurses and anaesthetic technicians may possess an S4 or schedule 8 (S8) medicine, if the medicine is possessed under the supervision of a registered nurse, midwife, dentist or medical practitioner; update references to reflect the revised Commonwealth Poisons Standard; remove all references to, and authorisations for, restricted ivermectin to reflect updated Therapeutic Goods Administration (TGA) guidelines; and update reference to a new version of the Queensland Ambulance Service Extended Practice Authority (QAS EPA) to: <ul style="list-style-type: none"> include cefazolin and olanzapine in the list of authorised medicines; align the medicines listed in the QAS EPA with the revised pharmacology inventory list for Retrieval Services Queensland so flight paramedics can continue to provide timely services in collaboration with Retrieval Services Queensland; and recognise an alternate qualification pathway for ambulance officers to be authorised as an Isolated Practice Area Paramedic. <p>Queensland Health has assessed the amendments and identified that the proposal improves access to scheduled medicines and health services by enabling suitably qualified pharmacists participating in the Pharmacy Pilot to supply and prescribe a wider range of medicines for common health conditions, health and wellbeing services and as part of chronic disease management protocols. The proposal is designed to reduce the burden of regulation and facilitate equitable access to medicines and health services for Queenslanders. This will be of particular benefit to persons who have limited access to primary health care services in rural and remote areas and may improve access for First Nations people across Queensland. The changes will also offer consumers greater choice in accessing health services.</p> <p>The proposal makes a number of minor and technical amendments to the Medicines Regulation to update the QAS EPA, clarify authorisations for enrolled nurses and anaesthetic technicians and update references to the Poisons Standard and TGA guidelines. These amendments improve clarity and accuracy and support timely access to health care and services for Queenslanders. Queensland Health has identified that no further regulatory impact analysis is required under the <i>Queensland Government Better Regulation Policy</i>.</p>
--	--

*Refer to [The Queensland Government Better Regulation Policy](#) for regulatory proposals not requiring regulatory impact analysis (for example, public sector management, changes to existing criminal laws, taxation).

Signed

Michael Walsh

A/Director-General, Queensland Health

Date: 15/11/2023

Shannon Fentiman MP

Minister for Health, Mental Health and Ambulance Services and
Minister for Women

Date: 22/11/2023